Intravitreal bevacizumab in myopic neovascular membranes: 24-month results

Ophthalmology. 2013 Jul;120(7):1510-1.e1. doi: 10.1016/j.ophtha.2013.03.006.
No abstract available

Publication types

  • Comparative Study
  • Letter
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Bevacizumab
  • Choroidal Neovascularization / diagnosis
  • Choroidal Neovascularization / drug therapy*
  • Choroidal Neovascularization / physiopathology
  • Female
  • Fluorescein Angiography
  • Humans
  • Intravitreal Injections
  • Male
  • Myopia, Degenerative / diagnosis
  • Myopia, Degenerative / drug therapy*
  • Myopia, Degenerative / physiopathology
  • Photochemotherapy*
  • Prospective Studies
  • Retina / pathology
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Visual Acuity / physiology

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab